Table 2.
Patients included in the study
| Study number | Study popul-ation | ARR | Serum aldosterone (nmol/L) | CT | 131I-chol-scint | AVS | Diagnose | PAD | |
|---|---|---|---|---|---|---|---|---|---|
| 1 |
14 |
NSP |
1.30 |
0.69 |
- |
- |
- |
AH |
|
| 2 |
1042 |
NSP |
2.50 |
0.54 |
+ (L) |
- |
- |
AH |
|
| 3 |
1052 |
NSP |
3.10 |
0.46 |
/ |
/ |
/ |
Normal |
|
| 4 |
1065 |
NSP |
4.30 |
0.64 |
+ (R) |
- |
Excluded |
|
|
| 5 |
1092 |
NSP |
1.50 |
0.75 |
/ |
/ |
/ |
Normal |
|
| 6 |
1105 |
NSP |
2.00 |
0.62 |
/ |
/ |
/ |
Normal |
|
| 7 |
2002 |
SP |
2.10 |
0.60 |
/ |
/ |
/ |
Normal |
|
| 8 |
2006 |
SP |
3.80 |
0.49 |
- (x2) |
+ (B) |
+ (L) |
APA (L) |
NAH |
| 9 |
2007 |
SP |
4.30 |
0.64 |
+ (R) |
- |
+ (R) |
APA (R) |
NAH |
| 10 |
2010 |
SP |
2.90 |
0.43 |
-(?L) |
- |
+ (L?) |
APA/AH |
Adenoma |
| 11 |
2014 |
SP |
4.50 |
0.68 |
- |
- (?R) |
+ (R) |
APA (R) |
NAH |
| 12 |
2022 |
SP |
6.80 |
1.29 |
- |
- |
- |
AH |
|
| 13 |
2036 |
SP |
2.90 |
0.43 |
/ |
/ |
/ |
Normal |
|
| 14 |
2037 |
SP |
4.50 |
0.95 |
/ |
/ |
/ |
Normal |
|
| 15 |
2042 |
SP |
1.70 |
0.44 |
- |
- |
+ (L) |
APA (L) |
NAH |
| 16 |
2049 |
SP |
9.30 |
1.39 |
+ |
- |
Excluded |
|
|
| 17 |
2060 |
SP |
3.30 |
0.89 |
+ (R) |
- |
+ (R) |
APA (R) |
|
| 18 |
2069 |
SP |
1.64 |
0.56 |
/ |
/ |
/ |
Normal |
|
| 19 |
2070 |
SP |
2.40 |
0.88 |
+ (L) |
- |
- |
AH |
|
| 20 |
2074 |
SP |
4.95 |
0.65 |
- |
/ |
/ |
AH |
|
| 21 |
2082 |
SP |
3.80 |
0.50 |
- |
/ |
/ |
AH |
|
| 22 |
2083 |
SP |
2.10 |
1.10 |
+ (R) |
+ (R) |
+ (R) |
APA (R) |
Adenoma |
| 23 |
2084 |
SP |
3.90 |
0.86 |
- |
+ (L) |
+ (L) |
APA (L) |
Adenoma |
| 24 |
2086 |
SP |
1.40 |
0.60 |
+ (L) |
- |
+ (L) |
APA (L) |
NAH |
| 25 |
2099 |
SP |
7.20 |
1.69 |
+ (L) |
- |
+ (L) |
APA (L) |
Adenoma |
| 26 |
2100 |
SP |
3.80 |
0.50 |
/ |
/ |
/ |
Normal |
|
| 27 |
3005 |
SP |
2.10 |
0.62 |
- |
|
Excluded |
|
|
| 28 | 3006 | SP | 3.50 | 0.94 | - | - | failed |
Population defines if the patient was screened in a non-selective (NSP) or a selective (SP) hypertensive population. Values for serum aldosterone and the ratio of s-aldosterone/plasma renin activity (ARR) at inclusion and results of the adrenal CT (CT), 131I-norcholesterol-scintigraphy (131I-chol-scint) and adrenal vein sampling (AVS) are given. For the CT, 131I-chol-scint and AVS the following symbols are used +, - , / and failed, for positive, bilateral overproduction of aldosterone, not executed and failed investigation respectively. The letters (L), (R) and (B) indicate left, right and bilateral respectively. In the diagnose column, Normal, AH and APA are used for normal ie no hyperaldosteronism, adrenal hyperplasia and aldosterone producing adenoma respectively. In the PAD column, NAH is used for cortical nodular hyperplasia and adenoma for cortical adenoma.